Search

• GSK presents promising phase 2a data for chronic hepatitis B treatment

  Media

  Chronic hepatitis B is a major global health problem that occurs when the body’s immune system is unable to fight off the virus.

  https://www.gsk.com/en-gb/media/press-releases/gsk-presents-promising-phase-2a-data-for-chronic-hepatitis-b-treatment/

  First published: 28 August 2020

• ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available

  Media

  Fostemsavir addresses a critical unmet need in HIV care for those with little to no treatment options left.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-chmp-opinion-for-rukobia-fostemsavir/

  First published: 11 December 2020

• ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

  Media

  Fostemsavir addresses a critical need for those with little to no treatment options left who are at risk of further disease progression

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-marketing-authorisation-for-rukobia-fostemsavir-a-first-in-class-attachment-inhibitor-in-combination-with-other-antiretrovirals/

  First published: 08 February 2021

• Tony Wood appointed Chief Scientific Officer designate, GSK

  Media

  Tony Wood appointed Chief Scientific Officer designate, GSK

  https://www.gsk.com/en-gb/media/press-releases/tony-wood-appointed-chief-scientific-officer-designate-gsk/

  First published: 19 January 2022

• ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment

  Media

  HIV care is a long-term prospect for those living with the disease, requiring life-long adherence to treatment.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment/

  First published: 16 August 2016

• ViiV Healthcare gains CHMP positive opinion for Juluca (dolutegravir/rilpivirine) in Europe

  Media

  ViiV Healthcare announced that the European Committee for Medicinal Products for Human Use issued a Positive Opinion for Juluca.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/

  First published: 23 March 2018

• 

  The 40 year fight against HIV

  Behind the science magazine

  How to find a treatment for a disease with no idea what that disease actually is

  https://www.gsk.com/en-gb/behind-the-science-magazine/the-40-year-fight-against-hiv/

  First published: 30 May 2022

• GSK welcomes key agreement to support global preparedness against pandemic influenza

  Media

  GSK welcomes agreement reached at OEWG coordinated by WHO on a Framework to support global preparedness for a future influenza pandemic.

  https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-key-agreement-to-support-global-preparedness-against-pandemic-influenza/

  First published: 18 April 2011

• Emergence of a new H1N1 influenza A strain (swine influenza)

  Media

  GSK is closely monitoring H1N1 strain in Mexico, US, Canada, France, Spain & New Zealand. WHO stated, situation a cause for concern.

  https://www.gsk.com/en-gb/media/press-releases/emergence-of-a-new-h1n1-influenza-a-strain-swine-influenza/

  First published: 26 April 2009

• ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV

  Media

  ViiV Healthcare announced results from phase III BRIGHTE study of fostemsavir

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv/

  First published: 27 October 2017